We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
51538 680 3 BTK
Emcee:  Biomaven Type:  Moderated
Biotech stocks are a close second only to internet stocks in how difficult they are to objectively value. This means that biotech stocks can be wildly under- or over-valued, which creates an opportunity for either profit or frustration for an investor that "knows better than market." To paraphrase the master: "Every now and again you should look at the stock price to see if the market is offering to do anything stupid."

This thread grew out of the "Munch-a-Biotech" thread, and is meant to discuss biotech stock valuation methods of all sorts, as well as particular stocks or sectors you may feel are under- or over-valued.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51538Yes, I agree with your reasoning. The news might have acted as a trigger for prA.J. Mullen-Thursday
51537I agree with your thoughts on the drop being disproportional to the news. I wilFiloF-Thursday
51536Even if the results were such that development of the drug were abandoned compleA.J. Mullen-Wednesday
51535As you note, the non-Hodgkin's lymphoma drug is only in Phase 1, and it coulArt Bechhoefer-Wednesday
51534CRSP was down 14% today. Results of a Phase I trial were just published. 11 paA.J. Mullen-Wednesday
51533Alnylam reports positive results for Phase III trial in children under 6 of drugA.J. Mullen-September 30
51532Watch NWBO for the next few days, I'm uncertain if TLD will be revealed, or Gary Mohilner-September 29
51531Quick comparison of PFE/BNTX and MRNA phase-3 protocols: investorshub.advfn.comDewDiligence_on_SI-September 17
51530Thanks Dew, I've trimmed off the 33% which still leaves me with a double uniA.J. Mullen-September 16
51529Yes, it's presumably a negative from a business standpoint. However, it may DewDiligence_on_SI-September 16
51528I just saw that, ILMN and Grail. Wouldn't that be a negative for NVTA, if tA.J. Mullen-September 16
51527Possibly related to ILMN's looming buyout of Grail for $1.9B: endpts.comDewDiligence_on_SI-September 16
51526Does anyone have a suggestion as to why NVTA is up 33% in 8 days?A.J. Mullen-September 16
51525Does anyone know how "rapid testing" is going to be done for COVID-19 Kirk ©-September 14
51524They enforced masks. Will do it with vaccines.Mr.Gogo-September 13
51523The COVID-19 vaccine trials are double-blind in theory; however, some vaccine-arDewDiligence_on_SI1September 12
51522Open label testing seems to be replacing double blind testing with control groupArt Bechhoefer-September 12
51521Thread on PFE/BNTX phase-3 enrollment expansion [scan up]: CommentDewDiligence_on_SI-September 12
51520Here's an interesting article on C-19 testing. It involves two major corporaOldAIMGuy1September 11
51519RMG Insight Investment Astronomy Photographer of the Year competition lots of software salesperson-September 10
51518My understanding is that the purpose of trials is to put metrics on the benefitsSpekulatius1September 9
51517My guess is that the benefit of suboptimal vaccines will far exceed the AE'sA.J. Mullen4September 9
51516Plus Moderna will use the monies received to buttress a brand new platform whichhandyman-September 9
51515>>Setting a target date of November 1st, before any data is available, is IRWIN JAMES FRANKEL1September 4
51514>>The suggestion that Pfizer and Moderna vaccines will prevail over competIRWIN JAMES FRANKEL1September 4
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):